Defence Therapeutics Inc Class A · CSE:DTC
Defence Therapeutics Inc Class A — Investor Presentation (April 2023)
20 slides from Defence Therapeutics Inc Class A's investor presentation, April 2023
Slide 1: Corporate Deck: Biopharmaceutical Innovations for Future Generations
Corporate Deck Biopharmaceutical Innovations for Future Generations Q2 2023
Slide 2: Forward Looking Statements
Corporate Deck | Defence Theurapeutics Forward Looking Statements DEFENCE THERAPEUTICS This presentation contains “forward-looking information” within the meaning Defence’s short operating history; the possibility that Defence may never receive of applicable securities laws in Canada, including stat
Slide 3: Making a Global (Patient) Impact
Making a Global (Patient) Impact As Canadian scientific pioneers, Defence Therapeutics is uncovering impactful medical treatments - for immuno-oncology and infectious diseases - with proprietary platform and biopharmaceutical innovations. Thanks for following our journey. 3
Slide 4: Innovating Pathways to Success
Innovating Pathways First to develop a combined breakthrough, with Proprietary and versatile technology targeting Problem-driven solutions confirming strong market Exponential scaling potential, with fully owned assets to be capitalized to Success precision and efficient cell nucleus drug delivery. im
Slide 5: Board Members, Advisors and Management
Board Members, Advisors and Management Corporate Deck | Defence Therapeutics 5
Slide 6: A Scalable Model
A Scalable Model ACCUM™ TECHNOLOGY 100% Owned ● Primary assets: Clinical research, Antibody Drug Conjugates (ADC) Platform, ACCUM™ Technology v ● Proprietary and US patented platform technology with proven enhanced drug delivery method ● Applications in oncology, vaccine development, and nanotechnol
Slide 7: Problem Driven Solutions for Ineffective Treatments
7 Ineffective Treatments ● Radiation + chemotherapy can kill tumor cells but also healthy cells. ● Nuclear-targeted biopharmaceuticals struggle with molecular obstacles which has limited their possibility to become a therapeutic Problem standard for human diseases (i.e. cancer). Driven Next-Level In
Slide 8: Current Challenges: Immuno-oncology and Infectious Diseases
Corporate Deck | Defence Theurapeutics Current Challenges: Immuno-oncology (IO) & Infectious Diseases (ID) Standard of care is currently ineffective against disseminated cancers. Targeted biopharmaceuticals struggle with molecular obstacles, limiting their potential to become a therapeutic standard
Slide 9: Micro Innovations, Macro Opportunities
Corporate Deck | Defence Therapeutics Micro Innovations, SURGING DEMAND Macro Opportunities The growing elderly population, prevalence of chronic diseases and adoption of biopharmaceuticals globally are impacting demand. The biopharmaceutical space is ripe for innovation and investment to bring majo
Slide 10: Global Biopharma Market Pioneers
13.8% CAGR from 2018 to 2025 vs. Corporate Deck | Defence Theurapeutics $526 Global Market 3-6% for the global pharmaceuticals Billion Pioneers This indicates GLOBAL BIOPHARMA At 17% of the global biopharmaceuticals are pharmaceutical market, destined to dominate the biopharma is projected to overal
Slide 11: ACCUM Technology is a proprietary and US patented platform
eGFP-hGal3-Expressing DCs 10 µm ACCUM™ Technology is a proprietary and US patented platform, with proven enhanced intracellular drug delivery. antigen-x Accum™ We have tackled an industry-wide ADC challenge antigen-x of Nuclear Localization, using Accum™. (Damaged endosomes triggered by Accum™) This
Slide 12: Technology: Turning ADC challenges into proven platform solutions
Corporate Deck | Defence Theurapeutics Technology Turning ADC challenges into proven platform solutions Potential Significance of Accum™ Technology ACCUM™ Talk-Worthy Results ACCUM™ Innovative Approach Overcoming problematic cell recycling Antibody retains tumor cells CURRENT POOR Accum™ EFFICIENT 1
Slide 13: Highlights & Next Steps
Corporate Deck | Defence Therapeutics Highlights & Next Steps ● Completed pilots have proven Accum™ to be very stable, enabling higher drug retention, killing the infectious cell line by +2000x over comparable (approved) ADC, “T-DM1”. ● Recent mice trials have proven the ability of Accum™ to improve
Slide 14: Cancer Therapeutics
01 Corporate Deck | Defence Theurapeutics Cancer Therapeutics We are leveraging our Accum™ technology, to create novel immuno-oncology treatments. Through our ADC and AccuTOX, we have been specifically targeting Melanoma, Breast and Lung Cancers within Discovery and Preclinical work and have ADCs wit
Slide 15: Vaccine Development
02 Vaccine State of the Art Facilities Development Laboratory space of 140 m2, accommodating 12 highly qualified personnel and a wide range of equipment. Access in process to 12 high tech platforms Accelerated Vaccine Development: located at the Institute for Research in Cancer & Infectious Diseases
Slide 16: Advanced Vaccines
Corporate Deck | Defence Theurapeutics QUANTIFICATION FOR IFN-GAMMA PRODUCTION BY RESPONDING T CELLS (IN VITRO ANTIGEN-PRESENTING ASSAY) Advanced Vaccines 2000 1500 IFN-gamma (pg/ml) Benefiting from the multiplier ability of Accum™ (100x), 12.64x Defence Therapeutics can easily direct the science fro
Slide 17: Valuable Project Traction
DISCOVERY PRE-CLINICAL PHASE 1-2023 Valuable Corporate Deck | Defence Therapeutics PRODUCT INDICATION RESEARCH & NON-GLP GLP Q2 DEVELOPMENT Project Cell Vaccine ARM Solid Tumors Traction Protein Vaccine AccuVAC-PT007 Cervical Cancer AccuTOX AccuTOX-001 Melanoma, With a highly flexible Accum™ Breast p
Slide 18: Comparables
Comparables Theurapeutics Corporate Deck | Defence Therapeutics Roche Holding AG 40.18 USD JAN.23 Mersana Therapeutics Inc 6.53 USD JAN.23 2023 OTCMKTS: RHHBY +0.91 (2.32%) 2023 NASDAQ: MRSN +0.80 (13.96%) 18
Slide 19: The Highlights
Corporate Deck | Defence Therapeutics THE HIGHLIGHTS Defence Therapeutics ● A highly versatile, proprietary and patented Accum™ platform technology. ● Ability to enhance the potency of any Defence Therapeutic or partner product by at least 10-20X. ● Significant traction and pipeline within two progra
Slide 20: Connect
Connect (514) 947 - 2272 info@defencetherapeutics.com www.defencetherapeutics.com 1680 - 200 Burrard Street, Vancouver, BC, V6C 3L6
Defence Therapeutics — Investor Presentation (April 2023) on 6ix